Interferon-gamma release assays

Clinics in Laboratory Medicine

Volumn 34, Issue 2, 2014, Pages 337-349

  Belknap, Robert ^a   Daley, Charles L ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Interferon gamma release assays; Latent tuberculosis infection; QuantiFERON; T SPOT; Tuberculin skin test; Tuberculosis

Indexed keywords

ISONIAZID; PYRIDOXINE; RIFAMPICIN; RIFAPENTINE;

BCG VACCINATION; COST; DIAGNOSTIC KIT; DISEASE COURSE; EXPOSURE; HIGH RISK POPULATION; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LIVER TOXICITY; LOW RISK POPULATION; PRIORITY JOURNAL; REVIEW; SCREENING; TOXIC HEPATITIS; TUBERCULIN TEST; TUBERCULOSIS; MICROBIOLOGY;

HUMANS; INTERFERON-GAMMA RELEASE TESTS; TUBERCULOSIS;

EID: 84901286018     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2014.02.007     Document Type: Review

References (56)

1. World Health Organization Global Tuberculosis Report 2013 2013, World Health Organization, Geneva, Switzerland.
2. Centers for Disease Control and Prevention, Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000, 161:S221-S247.
3. Horsburgh C.R., Rubin E.J. Clinical practice. Latent tuberculosis infection in the United States. NEngl J Med 2011, 364(15):1441-1448.
4. Prasad T.S., Verma R., Kumar S., et al. Proteomic analysis of purified protein derivative of Mycobacterium tuberculosis. Clin Proteomics 2013, 10(1):8.
5. Mazurek M., Jereb J., Vernon A., et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010, 59(RR-5):1-25.
6. Walter N., Daley C.L. Tuberculosis and nontuberculous mycobacterial infection. Clinical Respiratory Medicine. 2012, 385-408. Elsevier Saunders, Philadelphia. S.G. Spiro, G.A. Silvestri, A. Agusti (Eds.).
7. Behr M.A. BCG-different strains, different vaccines?. Lancet Infect Dis 2002, 2(2):86-92.
8. Andersen P., Munk M.E., Pollock J.M., et al. Specific immune-based diagnosis of tuberculosis. Lancet 2000, 356(9235):1099-1104.
9. Adjemian J., Olivier K.N., Seitz A.E., et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012, 185(8):881-886.
10. Pai M., Denkinger C.M., Kik S.V., et al. Gamma interferon release assays for detection of mycobacterium tuberculosis infection. Clin Microbiol Rev 2014, 27(1):3-20.
11. Bennett D.E., Courval J.M., Onorato I., et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med 2008, 177(3):348-355.
12. Centers for Disease Control and Prevention (CDC) Trends in tuberculosis - United States, 2012. MMWR Morb Mortal Wkly Rep 2013, 62:201-205.
13. Cain K.P., Haley C.A., Armstrong L.R., et al. Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. Am J Respir Crit Care Med 2007, 175(1):75-79.
14. Walter N.D., Painter J., Parker M., et al. Persistent latent tuberculosis reactivation risk in United States immigrants. Am J Respir Crit Care Med 2014, 189(1):88-95.
15. Liu Y., Painter J.A., Posey D.L., et al. Estimating the impact of newly arrived foreign-born persons on tuberculosis in the United States. PLoS One 2012, 7(2):e32158.
16. Ricks P.M., Cain K.P., Oeltmann J.E., et al. Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the U.S., 2005-2009. PLoS One 2011, 6(11):e27405.
17. Linas B.P., Wong A.Y., Freedberg K.A., et al. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011, 184(5):590-601.
18. Ferebee S.H. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970, 26:28-106.
19. Barry C.E., Boshoff H.I., Dartois V., et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7(12):845-855.
20. Modlin R.L., Bloom B.R. TB or not TB: that is no longer the question. Sci Transl Med 2013, 5(213):213sr6.
21. Farhat M., Greenaway C., Pai M., et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?. Int J Tuberc Lung Dis 2006, 10(11):1192-1204.
22. Cellestis. QuantiFERON-TB Gold Package Insert. 2011. Available at:. Accessed January 28, 2014. http://www.cellestis.com/IRM/Content/pdf/QuantiFeron%20US%20VerJ_JULY2011_ttf.pdf.
23. Oxford Immunotec. T-SPOT.TB Package Insert. 2013. Available at:. Accessed January 28, 2014. http://www.tspot.com/wp-content/uploads/2012/01/PI-TB-US-v4.pdf.
24. Diel R., Loddenkemper R., Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 2010, 137(4):952-968.
25. Metcalfe J.Z., Everett C.K., Steingart K.R., et al. Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. JInfect Dis 2011, 204(Suppl 4):S1120-S1129.
26. Dorman S.E., Belknap R., Graviss E.A., et al. Interferon-gamma release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in Healthcare Workers in the United States. Am J Respir Crit Care Med 2014, 189(1):77-87.
27. Kim Y.J., Kim S.I., Kim Y.R., et al. Predictive value of interferon-gamma ELISPOT assay in HIV 1-infected patients in an intermediate tuberculosis-endemic area. AIDS Res Hum Retroviruses 2012, 28(9):1038-1043.
28. Lange B., Vavra M., Kern W.V., et al. Development of tuberculosis in immunocompromised patients with a positive tuberculosis-specific IGRA. Int J Tuberc Lung Dis 2012, 16(4):492-495.
29. Machingaidze S., Verver S., Mulenga H., et al. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. Am J Respir Crit Care Med 2012, 186(10):1051-1056.
30. Rangaka M.X., Wilkinson K.A., Glynn J.R., et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(1):45-55.
31. Arend S.M., Thijsen S.F., Leyten E.M., et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med 2007, 175(6):618-627.
32. Diel R., Loddenkemper R., Meywald-Walter K., et al. Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold in Tube assay, and T-Spot.TB test in contact investigations for tuberculosis. Chest 2009, 135(4):1010-1018.
33. Aichelburg M.C., Rieger A., Breitenecker F., et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009, 48(7):954-962.
34. Cattamanchi A., Smith R., Steingart K.R., et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. JAcquir Immune Defic Syndr 2011, 56(3):230-238.
35. Slovis B.S., Plitman J.D., Haas D.W. The case against anergy testing as a routine adjunct to tuberculin skin testing. JAMA 2000, 283(15):2003-2007.
36. Talati N.J., Seybold U., Humphrey B., et al. Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis 2009, 9:15.
37. Gray J., Reves R., Johnson S., et al. Identification of false-positive QuantiFERON-TB Gold In-Tube assays by repeat testing in HIV-infected patients at low risk for tuberculosis. Clin Infect Dis 2012, 54(3):e20-e23.
38. Smith R., Cattamanchi A., Steingart K.R., et al. Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 2011, 23(4):377-384.
39. Chung W.K., Zheng Z.L., Sung J.Y., et al. Validity of interferon-gamma-release assays for the diagnosis of latent tuberculosis in haemodialysis patients. Clin Microbiol Infect 2010, 16(7):960-965.
40. Leung C.C., Yam W.C., Yew W.W., et al. T-Spot.TB outperforms tuberculin skin test in predicting tuberculosis disease. Am J Respir Crit Care Med 2010, 182(6):834-840.
41. Kim E.Y., Lim J.E., Jung J.Y., et al. Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis 2009, 9:207.
42. Haustein T., Ridout D.A., Hartley J.C., et al. The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J 2009, 28(8):669-673.
43. Mandalakas A.M., Detjen A.K., Hesseling A.C., et al. Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2011, 15(8):1018-1032.
44. Larsen N.M., Biddle C.L., Sotir M.J., et al. Risk of tuberculin skin test conversion among health care workers: occupational versus community exposure and infection. Clin Infect Dis 2002, 35(7):796-801.
45. Gandra S., Scott W.S., Somaraju V., et al. Questionable effectiveness of the QuantiFERON-TB Gold Test (Cellestis) as a screening tool in healthcare workers. Infect Control Hosp Epidemiol 2010, 31(12):1279-1285.
46. Ringshausen F.C., Nienhaus A., Schablon A., et al. Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infect Dis 2010, 10:220.
47. Ringshausen F.C., Nienhaus A., Torres Costa J., et al. Within-subject variability of Mycobacterium tuberculosis-specific gamma interferon responses in German health care workers. Clin Vaccine Immunol 2011, 18(7):1176-1182.
48. Torres Costa J., Silva R., Ringshausen F.C., et al. Screening for tuberculosis and prediction of disease in Portuguese healthcare workers. JOccup Med Toxicol 2011, 6:19.
49. Slater M.L., Welland G., Pai M., et al. Challenges with QuantiFERON-TB Gold assay for large-scale, routine screening of U.S. healthcare workers. Am J Respir Crit Care Med 2013, 188(8):1005-1010.
50. Runyon E.H. Preventive treatment in tuberculosis: a statement by the Committee on Therapy, American Thoracic Society. Am Rev Respir Dis 1965, 91:297-298.
51. Lardizabal A., Passannante M., Kojakali F., et al. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006, 130(6):1712-1717.
52. Page K.R., Sifakis F., Montes de Oca R., et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006, 166(17):1863-1870.
53. Menzies D., Long R., Trajman A., et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008, 149(10):689-697.
54. Sterling T.R., Villarino M.E., Borisov A.S., et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. NEngl J Med 2011, 365(23):2155-2166.
55. Hong Kong Chest Service/Tuberculosis Research Centre, M.B.M.R.C., A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992, 145(1):36-41.
56. Diel R., Goletti D., Ferrara G., et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011, 37(1):88-99.